Amgen (AMGN) Wins Ruling in Bid to Block Generic Otezla Until 2028, Loses Ruling on Otezla Patent That Expires in 2034 - Bloomberg

September 20, 2021 5:10 PM EDT

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Amgen (NASDAQ: AMGN) Wins Ruling in Bid to Block Generic Otezla Until 2028, Loses Ruling on Otezla Patent That Expires in 2034 - Bloomberg



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, Litigation